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Background: Breathlessness and exercise intolerance frequently impact the daily life of
patients with COPD.
Methods: This double-blind, multicentre, three-period crossover study randomised 111
patients with COPD (mean age 64 years, mean FEV1 38% of predicted normal) to budeso-
nide/formoterol 320/9 mg, formoterol 9 mg or placebo, twice daily for 1 week, following a 1-
week run-in period with 1-week wash-out between treatments. Terbutaline (0.5 mg/dose)
was used as needed. The primary efficacy variable was exercise endurance time (EET) at
75% peak work capacity with cycle ergometry assessed 1 h post-morning dose.
Results: Budesonide/formoterol prolonged EET 1 h post-morning dose versus formoterol by
69 s (P < 0.005) and placebo by 105 s (P < 0.0001) and improved inspiratory capacity (IC) at
isotime during exercise versus formoterol by 8% (P Z 0.011) and placebo by 16%
(P < 0.0001). Borg score at isotime was reduced by 0.48 (P Z 0.12) and 0.78 (P Z 0.014)
compared with formoterol and placebo, respectively. At the repeated cycle test 6 h after
morning dose, the effect on EET still favoured budesonide/formoterol over formoterol and
placebo, while the isotime IC and Borg score were similar but better than placebo for the
active study drugs. Budesonide/formoterol and formoterol improved health status (St George’s
Respiratory Questionnaire total score: mean difference versus placebo 2.4 and 2.2, respec-
tively). All treatments were well tolerated.
Conclusions: Budesonide/formoterol resulted in a significant improvement in endurance time
1 h after the last morning dose in a 1-week treatment period versus formoterol and placebo.rth, Akademisches Lehrkrankenhaus der Universita¨t Erlangen-Nu¨rnberg, Jakob-Henle-Str. 1,
7580 1101; fax: þ49 911 7580 1141.
erth.de (H. Worth).
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Exercise tolerance and budesonide/formoterol in COPD 1451This study demonstrates, for the first time, the benefit of inhaled corticosteroids in addition to
long-acting b2-agonists on exercise tolerance in COPD patients.
www.clinicaltrials.gov registration number: NCT00489853.
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powder formulation Turbuhaler is currently not approved in
the US.Background
Two key goals for the management of patients with chronic
obstructive pulmonary disease (COPD) are to improve
respiratory symptoms and exercise tolerance.1 Breathless-
ness and exercise intolerance in COPD are frequent,2,3 and
limit patient ability to be physically active, resulting in
impairment of social and health-related quality of life.2
The Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines recommend long-acting bron-
chodilators, such as long-acting b2-agonists (LABAs; e.g.
formoterol and salmeterol) and long-acting muscarinic
antagonists (tiotropium) as maintenance treatments for
moderate to very severe COPD.1 Bronchodilators improve
exercise tolerance and breathlessness both at rest and
during exercise.1,3e7 Inhaled corticosteroids (ICS) are
reported to reduce the risk of exacerbations and slow the
rate of decline of health-related quality of life in symp-
tomatic COPD patients.8e11
Several randomised, double-blind clinical studies have
shown that treatment with ICS combined with LABA
(budesonide/formoterol or salmeterol/fluticasone) is more
effective than the individual components at reducing
exacerbations and improving lung function, including
inspiratory capacity (IC),12 as well as improving health
status.12e18 A beneficial effect on exercise tolerance has
not been reported to date for ICS/LABA combination ther-
apies over treatment with LABA alone;1 however, one study
has shown the beneficial effect of ICS/LABA combination
therapy over placebo, although with no significant effects
over LABA alone.19 The objective of this study was to
investigate whether an ICS, budesonide, may contribute to
an improvement of exercise tolerance in patients with
COPD when given in fixed combination with a LABA, for-
moterol, i.e. as budesonide/formoterol, compared with
formoterol alone, and placebo.
Methods
Study subjects
This was a randomised, double-blind, active and placebo-
controlled, crossover study (www.clinicaltrials.gov regis-
tration number: NCT00489853) involving outpatients with
COPD, a history of one or more exacerbations of COPD
requiring a course of oral steroids and/or antibiotics within
the last 12 months, a pre-bronchodilator (i.e. trough value)
forced expiratory volume in 1 s (FEV1) 50% of predicted
normal and a functional residual capacity (FRC), measured
by body plethysmography, of more than 120% of predicted
normal. See the online supplement for further details on
eligibility criteria. The study was conducted at 13 centres in
Germany and Switzerland, and was performed according to
the Declaration of Helsinki and Good Clinical Practiceguidelines. Independent ethics committees approved the
study. Written informed consent was obtained from all
patients.
Study design
The study comprised nine visits with a follow-up telephone
call assessment of adverse events 1 week after visit 9.
Patient flow through the study and the study design are
shown in Figs. 1 and 2, respectively. At visit 1, eligible
patients entered a 1-week run-in period during which ipra-
tropium bromide (Atrovent, Boehringer Ingelheim,
Germany), 40 mg/dose, three or four inhalations daily, was
used as maintenance medication. Patients fulfilling the
randomisation criteria entered three 1-week treatment
periods with a 1-week wash-out period between treatments.
During treatment periods 1, 2 and 3, patients received
one of the six possible treatment sequences: budesonide/
formoterol (Symbicort Turbuhalerf, AstraZeneca, Lund,
Sweden) 320/9 mg one inhalation twice daily; formoterol
(administered as Oxis Turbuhaler; AstraZeneca, Lund,
Sweden) 9 mg one inhalation twice daily; or placebo (Tur-
buhaler matching the Symbicort Turbuhaler or Oxis Tur-
buhaler, one inhalation twice daily). Ipratropium bromide
was used as maintenance medication during run-in and the
wash-out periods and terbutaline sulphate (Bricanyl Tur-
buhaler, AstraZeneca, Lund, Sweden; 0.5mg/dose) was used
throughout the study as reliever medication in all treatment
arms. Randomisation codes were assigned from a computer-
generated list at AstraZeneca. At each centre, participants
were randomised strictly sequentially as they became
eligible.
Exercise endurance time (EET) was measured using
a constant workload exercise test (CWET) performed at 75%
of maximum work capacity (Wmax) at the end of each
treatment period 1 and 6 h post-morning dose by cycle
ergometry. Recordings of St George’s Respiratory Ques-
tionnaire for COPD patients (SGRQ-C), spirometry (FEV1,
forced vital capacity [FVC] and vital capacity [VC]), body
plethysmography (residual volume [RV], IC, total lung
capacity and specific airway resistance [sRaw]) and dysp-
noea score (Borg CR10 scale) were measured pre-morning
dose and prior to the CWET, approximately 0.5 and 5.5 h
after investigational product intake. Dyspnoea score and IC
were also recorded every second minute during the CWETs.
Additionally, patients maintained an electronic diary (e-
Diary) log and electronic peak expiratory flow (PEF) records
throughout the study to monitor morning PEF, symptoms,
intake of investigational product and use of reliever
Figure 1 Patient flow. BUD Z budesonide; FORM Z formoterol.
1452 H. Worth et al.medication. Further details of the study design and
assessments are included in the online supplement.
Primary and secondary variables
The primary efficacy variable was EET at 1 h post-morning
dose. Secondary efficacy variables included EET at 75% of
Wmax 6 h post-morning dose and IC assessed every second
minute during the exercise tests (ICex).Figure 2 Study designPatient-reported outcomes comprised dyspnoea score
(Borg CR10 scale), SGRQ-C and symptoms commonly asso-
ciated with COPD (breathlessness, chest tightness, cough
and night-time awakenings). Further details of these
assessments are included in the online supplement. For ICex
and the Borg score measured during exercise, an isotime
was identified to compare parameters during exercise. For
each patient, isotime was defined as the shortest exercise
endurance time at any of the cycle tests. Interpolation. F/U Z follow-up.
Exercise tolerance and budesonide/formoterol in COPD 1453between the two nearest measurements of the isotime was
used to calculate the IC as well as the Borg score at isotime.
Tolerability was assessed by monitoring the nature and
incidence of adverse events.
Statistical analysis
All hypothesis testing was done using two-sided alternative
hypotheses with P-values <5% considered significant.
EET was analysed using an analysis of variance (ANOVA)
model with patient, period and treatment as fixed factors. A
multiplicative model was used to check the stability of the
EET results. Treatment differences were estimated from the
model and 95% confidence intervals (CI) calculated. For
body plethysmography parameters, a multiplicative ANOVA
model with patient, period and treatment as fixed factors
was used. Pre-dose spirometry measurements were ana-
lysed in a similar way but with the values from visits 4, 6 and
8 as the covariates (log-transformed). SpearmaneRank
correlations were performed to investigate the strength of
the relationship between changes in EET and ICex, EET and
Borg CR10 score, and ICex and Borg CR10 score for each of
the three treatment regimens. SGRQ-C at the end of each
treatment period and the variables recorded in the e-Diary
were analysed with a model similar to that used for the
primary variable, but with the corresponding run-in/wash-
out period mean for e-Diary variables as a covariate.
EET data for individual patients were also analysed and
categorised as being above, in-between or below the sug-
gested minimal important difference (MID) thresholds of
75 and 105 s. These two suggested MIDs were taken from
a review of MIDs for EET by cycle ergometry by the Amer-
ican Thoracic Society/European Respiratory Society Task
Force published by Cazzola and colleagues,20 where 75 s is
cited as the suggested MID for a submaximal EET and 105 s is
the higher MID value referred to in the review of relevant
literature and referring to analyses by Casaburi and
O’Donnell and colleagues.19e22
Adverse events were analysed by means of descriptive
statistics and qualitative analysis.
Further details of the statistical analysis can be found in
the online supplement.
Results
Study subjects
A total of 137 patients were enrolled between August 2007
and August 2008. One hundred and eleven patients were
randomised and 91 completed the study. A total of 20
patients discontinued the study (Fig. 1). Randomised
patients had a mean age of 63.7 years (range: 42e83 years),
mean FEV1 was 1.1 l (37.5% predicted normal, standard
deviation: 8.4) and mean Wmax was 63 W (Table 1). Further
patient demographics and baseline characteristics are
provided in Table 1.
EET at 1 h post-dose
Analysis of mean EETs, using an ANOVA model, 1 h post-dose
after 1 week of treatment with budesonide/formoterol,formoterol or placebo were 517, 448 and 412 s, respec-
tively, resulting in mean differences of 69 s and 105 s
for budesonide/formoterol versus formoterol (P < 0.005)
and placebo (P < 0.0001), respectively (Fig. 3 and
Supplementary Table 1). This corresponds to a 14% and 28%
increase in EET, respectively, as calculated from a multi-
plicative ANOVA model. No significant difference in mean
EET at 1 h post-dose was seen between the formoterol and
placebo groups (PZ 0.09). Median EETwas 6e7 min (range:
1e30 min). More patients during the budesonide/for-
moterol treatment period had EETs above both the 75 and
105 s MID thresholds compared with placebo than during
the formoterol period at 1 h post-dose (Table 2).
The most common reason given for terminating the
exercise test was breathlessness in all groups at both 1 and
6 h post-dose (Supplementary Table 2). More patients
stated leg fatigue as a reason for termination in the
budesonide/formoterol group compared with the other
groups (17%, 10% and 9% with budesonide/formoterol, for-
moterol and placebo, respectively).
EET at 6 h post-dose
Mean EETs 6 h post-dose after 1 week of treatment with
budesonide/formoterol, formoterol or placebo were 456,
413 and 394 s, respectively, resulting in mean differences of
42 s and 62 s for budesonide/formoterol versus formoterol
(P < 0.05) and placebo (P < 0.005), respectively (Fig. 3 and
Supplementary Table 1). This corresponds to a 12% and
20% increase in EET, respectively. There was no difference
in EET between formoterol and placebo (P Z 0.33).
Measurements at 6 h post-dose showed that more patients
in the budesonide/formoterol treatment period had EETs
above the 75 s MID threshold than during the formoterol
treatment period (Table 2).
The reasons given for terminating the exercise tests
were similar to those at 1 h post-morning dose and are
provided in Supplementary Table 2.
ICex 1 and 6 h post-dose
At 1 h post-morning dose, budesonide/formoterol improved
IC at isotime compared with both placebo (ratio: 1.16; 95%
CI: 1.093, 1.227; P < 0.0001) and formoterol (ratio: 1.08;
95% CI: 1.018, 1.142; P Z 0.011) (Fig. 4A). At 6 h post-
morning dose, budesonide/formoterol did not improve IC
compared with placebo (ratio: 1.08; 95% CI: 0.998, 1.166;
P Z 0.06) or formoterol (P Z 0.93).
Borg score 1 and 6 h post-dose
Budesonide/formoterol improved Borg score measurements
at isotime compared with placebo at 1 h post-dose
(difference: 0.8; 95% CI: 1.360, 0.155; P Z 0.014) but
no other significant differences were seen. At 6 h post-
dose, both active treatments significantly improved Borg
score compared with placebo but there was no difference
between the two treatments (budesonide/formoterol
difference: 1.1; 95% CI: 1.664, 0.479; P Z 0.0005 and
formoterol difference: 1.1; 95% CI: 1.679, 0.497;
P Z 0.0004) (Fig. 4B).
Table 1 Baseline patient characteristics.
Characteristic All (N Z 111)
Male, n (%) 84 (76)
Age, years 63.7 (42e83)
Body mass index (kg/m2) 25.7 (16e37)
Time since diagnosis, median years (IQR) 7.0 (4)
Previous smokers, n (%) 68 (61)
Pack-years of smoking, median (IQR) 35 (10)
Medications used at entry, n (%)
ICS 43 (39)
LAMA 49 (44)
LABA 96 (86)
LABA þ LAMA 38 (34)
LABA þ LAMA þ ICS 17 (15)
FEV1, l (SD) 1.1 (0.3)
FVC, l (SD) 2.2 (0.7)
FEV1, % PN (SD) 37.5 (8.4)
FEV1 reversibility, % PN (SD) 4.3 (4.9)
Reliever use, no. inhalations/24 h 4.1 (0.0e16.6)
Symptom scores (scale 0e4)
Breathlessness Mean (range) 1.6 (0.0e3.3)
Median 1.6
Chest tightness Mean (range) 1.2 (0.0e3.3)
Median 1.0
Cough Mean (range) 1.6 (0.0e3.2)
Median 1.6
Night-time awakenings Mean (range) 0.6 (0.0e2.0)
Median 0.4
Maximum work load (watts) 63.2 (20.0e150.0)
SGRQ-C total score 53.0 (7.9e90.6)
SGRQ-C symptom domain 69.0 (23.9e97.1)
SGRQ-C activity domain 66.7 (0.0e100.0)
SGRQ-C impact domain 39.3 (2.1e88.6)
Data expressed as means (range) unless otherwise indicated. FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity;
ICS Z inhaled corticosteroids; IQR Z interquartile range; LABA Z long-acting b2-agonist; LAMA Z long-acting muscarinic antagonist;
PN Z predicted normal; SD Z standard deviation; SGRQ-C Z St George’s Respiratory Questionnaire for COPD patients.
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CR10 score
A positive correlation between EET and ICex at isotime was
seen at 1 h and also at 6 h post-dose. However, no statis-
tically significant correlations were seen between EET and
Borg CR10 score or between ICex and Borg CR10 score at 1 h
post-dose.
Lung function
Budesonide/formoterol improved pre-dose FEV1, FVC, VC
and IC (1 h post-dose) compared with placebo by 10%, 7%,
6% and 14%, respectively (P < 0.0001, P < 0.0005, P < 0.005
and P < 0.0001, respectively), and FEV1 by 5% compared
with formoterol (P < 0.05). Treatment with formoterol was
superior to placebo for all measurements (Supplementary
Table 3).
Budesonide/formoterol was superior to placebo for all
body plethysmography variables (FRC, RV and sRaw) except
total lung capacity at both 1 h and 6 h post-morning dose(Supplementary Table 3). No significant differences were
detected in any of these variables for budesonide/for-
moterol compared with formoterol.
Patient-reported outcomes
Treatment with budesonide/formoterol and formoterol
were both superior to placebo for all diary card variables,
symptoms associated with COPD (breathlessness, chest
tightness, cough and night-time awakenings), morning PEF
and reliever medication use (Supplementary Table 4).
Budesonide/formoterol was superior to formoterol
regarding night-time awakenings. Budesonide/formoterol
treatment resulted in significant improvements in SGRQ-C
total score compared with placebo (2.44, P < 0.01), and
in both the symptom (2.67, P < 0.05) and impact (3.03,
P < 0.01) domains, also compared with placebo. No
difference was found between budesonide/formoterol and
formoterol. Formoterol was superior to placebo in SGRQ-C
total score (2.2, P < 0.05) and impact domain score
(3.59, P < 0.005).
Figure 3 Exercise endurance time analysis 1 and 6 h post-
morning dose. BUD Z budesonide; EET Z exercise endurance
time; FORM Z formoterol; Wmax Z maximum work capacity.
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All treatments were well tolerated and no safety concerns
were identified (Table 3). Four serious adverse events (two,
one and one in the budesonide/formoterol, formoterol and
placebo groups, respectively), but no deaths, occurredTable 2 Percentage of patients in each threshold category defin
post-morning dose EET.
Threshold(s)/treatment Pe
W
EET duration compared with
placebo 1 h post-dose
75
- BUD/FORM 7
- FORM 15
105
- BUD/FORM 5
- FORM 12
EET duration compared with
placebo 6 h post-dose
75
- BUD/FORM 11
- FORM 22
105
- BUD/FORM 10
- FORM 14
BUD/FORM Z budesonide/formoterol; FORM Z formoterol.
*McNemar’s test of homogeneity of pairwise matched categorical data
only for better versus not better (combination of worse and in-betweduring the study. None of the serious adverse events were
judged to be related to study drug treatment.
Discussion
This study reports for the first time that adding an ICS to
a LABA results in a significant improvement in EET in
patients with COPD compared with a LABA alone. Treat-
ment with a fixed combination of budesonide/formoterol
resulted in significantly improved EETs of 69 (14%) and 105
(28%) seconds at 1 h post-dose versus formoterol and
placebo, respectively. Based on the MID cut-offs of 75 and
105 s, as suggested by the ATS/ERS Task Force in the
publication on outcomes for COPD in clinical trials,20
the prolonged EETs seen with budesonide/formoterol
compared with formoterol alone reflect a significantly
greater proportion of patients having an important
improvement (44% versus 31% and 39% versus 26% reaching
the MID cut-points of 75 and 105 s, respectively20,21) in
exercise tolerance. The improvements in EET with bude-
sonide/formoterol treatment were to a large extent main-
tained at 6 h post-morning dose (42-s [12%] and 62-s [20%]
improvements compared with formoterol alone and
placebo, respectively). This sustained improvement in
exercise endurance post-morning dose could have benefi-
cial real-life implications for patients’ abilities to carry out
morning activities, encouraging them to increase their
overall activity levels, which may lead to improvements in
health status.23,24 This may be of particular clinical
importance as most patients with severe COPD identify
morning as the time when their COPD is worst and when
they suffer especially with breathlessness that can hinder
their ability to perform essential morning activities.2
A relationship between IC and exercise tolerance has
been shown previously.25 Consistent with this observation,
budesonide/formoterol improved isotime ICex at 1 h post-
morning dose compared with formoterol and at 1 and 6 h
compared with placebo. The beneficial effect on IC duringed by EET duration compared with placebo for the 1 h and 6 h
rformance vs. placebo (% patients) P-value*
orse In-between Better
.8 47.8 44.4 0.018
.6 53.3 31.1
.6 55.6 38.9 0.021
.2 62.2 25.6
.2 50.6 38.2 0.015
.5 50.6 27.0
.1 58.4 31.5 0.212
.6 61.8 23.6
for budesonide/formoterol versus formoterol. This test compares
en).
Figure 4 Improvement in IC at isotime measured 1 and 6 h
post-morning dose. BUD Z budesonide; FORM Z formoterol;
IC Z inspiratory capacity.
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contribute towards the prolongation of EET. Furthermore,
correlation analyses in the present study detected corre-
lations between EET, ICex and Borg score for breathlessnessTable 3 Summary of adverse events.
PB
n
Number (%) of patients who had an adverse
event (AE) in each category
Any AE 13
Serious adverse events (SAEs)
leading to death
0
SAEs other than death* 1
Discontinuations due to adverse event (DAEs) 7
Other significant AEs 0
Total number of AEs
Any AE 15
Maximum number of AEs/patient 2
Causally related AEs 2
SAEs (fatal and non-fatal) 1
Causally related AEs (fatal and non-fatal) 0
DAEs 7
Other significant AEs 0
*One SAE due to COPD in each arm, and one SAE due to wrist injury
AE Z adverse event; BUD Z budesonide; DAE Z discontinuation
SAE Z serious adverse event.at isotime, consistent with observations made by O’Donnell
and colleagues.19,26
Impairment of exercise endurance in COPD patients can
also occur because of deconditioning and abnormalities in
skeletal muscles secondary to COPD.27 In the present study,
breathlessness dominated as the reason for termination of
the exercise test; however, when treated with formoterol,
and particularly budesonide/formoterol, numerically more
patients stated leg fatigue as the reason for exercise test
termination. A possible explanation for this finding is that
breathlessness due to a decrease in IC was a less usual exer-
cise-limiting factor with active drug treatment, allowing the
patients to continue cycling until they had to stop due to
muscle fatigue. The beneficial effects of LABAs and anticho-
linergic bronchodilators on exercise tolerance are well
known3e7,19,26; however, theadditional effectsof ICS aloneor
in combination with LABA have not been previously docu-
mented. A study looking at the effect of combination treat-
ment with salmeterol/fluticasone propionate on exercise
tolerance in COPD patients partly support our findings by
showing a significant increase in EET compared with placebo
and a non-tested trend compared with salmeterol alone.19
The effects on EET of budesonide added to formoterol
over formoterol alone could have several explanations.
Firstly, there may be complementary interactions between
formoterol and budesonide arising from b2-agonist modu-
lation of glucocorticoid receptor function as well as
corticosteroid-mediated modulation of b2-receptor func-
tion.28,29 Another explanation may be the immediate,
so-called non-genomic actions of budesonide mediated by
effects on cells or vasculature.30e33 In this respect, it has
been shown by Cazzola and co-workers that the addition of
budesonide to formoterol provides a larger increase in FEV1,
as soon as 15 min after inhalation compared with for-
moterol alone,30 and theoretically this may result in
further prolongation of EET. Moreover, in another study, theO
Z 104
FORM
n Z 102
BUD/FORM
n Z 100
(13) 8 (8) 8 (8)
0 0
(1) 1 (1) 2 (2)
(7) 4 (4) 6 (6)
0 0
9 8
2 1
0 0
1 2
0 0
4 6
0 0
in the BUD/FORM arm.
due to adverse event; FORM Z formoterol; PBO Z placebo;
Exercise tolerance and budesonide/formoterol in COPD 1457same research group observed that the combined admin-
istration of formoterol and budesonide reduces the poten-
tial for acute negative effects of formoterol on blood-gas
tensions.34
Non-genomic actions of glucocorticosteroids have a
maximum effect within 2 h35 and a limited duration, which
may explainwhy the effect of budesonide/formoterol on EET
in this studywas not fullymaintained after 6 h. Furthermore,
it seems possible that the decrease in EET in all groups by
4%, 8% and 12% in the placebo, formoterol and budesonide/
formoterol groups, respectively, 6 h post-dose compared
with the test at 1 h could partly be explained by fatigue
from the exercise tests and also to the burden of other
assessments undertaken during the days spent in clinic.
In accordance with the results for night-time awakenings
and pre-dose FEV1 in the present study, it has been shown
that treatment with budesonide/formoterol results in
a decrease in night-time awakenings14,18 and higher pre-
dose FEV1
16,18 compared with formoterol alone. Sleep loss
is known to affect exercise endurance,36 thus, it is specu-
lated that patients treated with budesonide/formoterol
could have a better start in the morning than patients
treated with formoterol alone, which might lead to possi-
bilities for improved exercise tolerance in the morning.
Lastly, it could be that the anti-inflammatory component,
budesonide, contributes less towards improvement of static
outcomes; however, the effect becomes more evident
when patients are provoked by, for example, cold air,
exercise or infection, leading to worsening of symptoms or
even an exacerbation. In line with this concept, budeso-
nide/formoterol was found to be superior to formoterol on
dynamic hyperinflation during exercise, while no difference
was detected on ‘static hyperinflation’ in terms of IC
measured with plethysmography.
A pooled analysis has demonstrated the reliability of
cycle ergometry studies of EET in COPD patients.22,37 It
should, however, be noted that patient selection is impor-
tant. Patients who can cycle over longer time periods may
dramatically change the EET results. For example, two
patients in the tiotropium arm in a study by Maltais and
colleagues had EET values above 3000 s and after removal
from the analysis the difference versus placebo decreased
from 236 to 164 s.37 In the present study there was also
a well-trained cyclist included, with an EET over 1800 s.
However, a stability analysis, using a multiplicative model,
supports the EET results, showing a 14% improvement with
budesonide/formoterol compared with formoterol and
a 28% improvement compared with placebo. Another
problem in this study was the high number of patients who
could only cycle for 2e4 min, presenting less time to detect
treatment effects. As a consequence of this finding, it may
be suggested that entry criteria in trials looking at EET
should exclude patients that are able to cycle for only short
or very long periods of time and that EET, IC and Borg scores
taken during cycle ergometry tests should also have been
measured at baseline. Another suggestion would be to use
a multiplicative statistical analysis that takes large baseline
variability into account. A relative improvement may be
very relevant for MIDs since an absolute improvement is
dependent on baseline EET, e.g. an MID improvement of 75
or 105 s would probably be more clinically relevant in
a population with low EETs compared with a populationwith high EETs at baseline. As stated by the ATS/ERS Task
Force,20 further investigations of the MID for submaximal
exercise are clearly warranted.
In this study all treatments were well tolerated and
there were no new tolerability and safety issues related to
any of the treatment regimens.
Conclusions
This study has shown that only 1 week of treatment with
budesonide/formoterol improves EET measured with an
endurance bicycle ergometry test at both 1 and 6 h post-
morning dose compared with formoterol or placebo. Bude-
sonide/formoterol was also shown to reduce dynamic
hyperinflation, as measured by IC during exercise, compared
with formoterol and placebo at 1 h. Both these findings
suggest that patients with COPD have a greater potential
for undertaking more demanding routine activities, directly
and for up to 6 h after their morning dose of budesonide/
formoterol, compared with a treatment regimen of for-
moterol alone. This study has shown, for the first time, that
the addition of an ICS to a LABA results in a significantly
greater proportion of patients with COPD having a clinically
important improvement in exercise endurance compared
with a LABA alone, and highlights the added value of the ICS
component, budesonide, on the LABA, formoterol.
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